Hướng dẫn chi tiết sắp ra mắt
Chúng tôi đang chuẩn bị hướng dẫn giáo dục toàn diện cho Cancer Survivorship Assessment. Quay lại sớm để xem giải thích từng bước, công thức, ví dụ thực tế và mẹo từ chuyên gia.
Cancer survivorship refers to the physical, psychological, social, and spiritual health and well-being of people who have been diagnosed with cancer from the time of diagnosis through the rest of their lives, including during active treatment and after treatment ends. The concept was formally defined by the US National Coalition for Cancer Survivorship (NCCS) in 1986 and has since become a distinct and growing clinical subspecialty. With over 18 million cancer survivors in the United States and growing numbers globally — a result of earlier diagnosis, more effective treatments, and an ageing population — survivorship medicine addresses the complex constellation of late effects, chronic toxicities, and ongoing care needs that extend far beyond cancer treatment itself. Treatment modalities cause distinct late effects: surgery (lymphoedema, altered anatomy, phantom pain, adhesions); radiation therapy (fibrosis, secondary malignancies, cardiovascular disease, cognitive effects, hypothyroidism in neck-irradiated patients); chemotherapy (peripheral neuropathy, cardiotoxicity, infertility, secondary cancers, cognitive impairment 'chemo brain'); and immunotherapy (immune-related adverse events that may persist for months to years). Psychological health is equally critical: anxiety and depression affect 20–40% of cancer survivors; fear of cancer recurrence (FCR) is the most common survivorship concern; post-traumatic stress disorder (PTSD) occurs in 10–15% of survivors. Comprehensive survivorship care plans — cancer treatment summaries, surveillance schedules, late effects monitoring, health promotion, and referral pathways — are now recommended by ASCO, ESMO, and NICE as a standard component of cancer care for all patients completing active treatment.
Survivorship assessment domains: Physical (fatigue, pain, neuropathy, cardiac, fertility, endocrine, secondary malignancy risk, lymphoedema); Psychological (depression PHQ-9, anxiety GAD-7, FCR, PTSD PCL-5); Social (employment, financial, relationships, sexuality); Spiritual (meaning, purpose); Surveillance schedule: modality-specific + tumour-specific; Late effects risk = cumulative treatment dose × individual susceptibility factors
- 1Create a personalised cancer treatment summary at the completion of active therapy: document cancer diagnosis (histology, stage, biomarkers), all treatments received (surgery details, chemotherapy agents and cumulative doses, radiation fields and doses, targeted therapies, immunotherapy), dates of treatment, and key toxicities experienced during treatment.
- 2Develop a survivorship care plan (SCP) that includes: planned surveillance schedule with frequency and type of investigations (e.g., CT scan every 6 months for 2 years in colorectal cancer; annual mammogram in breast cancer survivors); late effects monitoring tailored to the specific treatments received; and health promotion recommendations (exercise, weight management, smoking cessation, sun protection, bone density, cardiovascular risk reduction).
- 3Systematically assess physical late effects at survivorship consultations: fatigue (most prevalent — 20–40% of survivors; use FACIT-F scale); peripheral neuropathy (after taxane, vinca, platinum chemotherapy — assess using NRS and monofilament testing); cardiotoxicity (echocardiogram surveillance after anthracycline or trastuzumab; lipid and BP monitoring); endocrine late effects (thyroid function after neck radiation; gonadal function and menopausal symptoms after pelvic radiation or chemotherapy).
- 4Screen for psychological morbidity at every survivorship encounter using validated tools: PHQ-9 for depression; GAD-7 for anxiety; Fear of Cancer Recurrence Inventory (FCRI) or a single validated FCR question; PTSD Checklist (PCL-5); and patient-reported outcomes capturing quality of life (EORTC QLQ-C30 or PROMis Global Health).
- 5Address fertility and sexual health: all cancer survivors of reproductive age should be asked about fertility concerns; chemotherapy-induced ovarian failure is common after alkylating agents; sexual dysfunction affects 40–60% of breast and prostate cancer survivors; refer to specialist fertility and sexual health services as appropriate.
- 6Assess social and occupational function: return to work is a priority for most working-age survivors; financial toxicity from cancer treatment is common and undertreated; social isolation is a significant predictor of poor survivorship outcomes; prescribe structured rehabilitation where appropriate.
- 7Recommend evidence-based lifestyle interventions: aerobic exercise 150 min/week reduces cancer recurrence risk, improves fatigue, and reduces cardiovascular late-effect risk; resistance exercise preserves muscle mass lost during treatment; Mediterranean diet supports metabolic health; achieve and maintain healthy BMI; alcohol moderation; smoking cessation (ongoing smoking significantly worsens survivorship outcomes).
Anastrozole causes bone loss (~2% BMD/year); calcium 1200 mg + vitamin D 800 IU daily and weight-bearing exercise are mandatory supplements.
Breast cancer survivors on aromatase inhibitors require bone health monitoring, cardiovascular surveillance for anthracycline cardiotoxicity, and psychological support for fear of recurrence.
Oxaliplatin causes sensory neuropathy in >50% of patients; acute cold-induced neuropathy typically resolves; chronic neuropathy persists in 10–30% at 6 months.
FOLFOX (5-FU + leucovorin + oxaliplatin) is associated with peripheral neuropathy — the primary long-term physical late effect requiring ongoing assessment and management.
Radiation to the neck causes carotid artery disease in 30% of patients within 10 years — atherosclerotic risk is significantly elevated.
Head and neck chemoradiotherapy causes multiple overlapping late effects requiring multi-disciplinary survivorship review: dentistry, dietetics, speech and language therapy, audiology, endocrinology, and cardiology.
Fear of cancer recurrence affects 60–70% of cancer survivors and is the single most commonly reported survivorship concern.
Anxiety GAD-7 ≥10 and high FCR warrant clinical psychology referral; evidence-based interventions include CBT, mindfulness-based stress reduction, and acceptance and commitment therapy.
Cancer centres use survivorship care plans to coordinate post-treatment care between oncology teams and primary care physicians, ensuring late effects monitoring does not fall through the gap between specialties, enabling practitioners to make well-informed quantitative decisions based on validated computational methods and industry-standard approaches
General practitioners use survivorship care summaries to provide informed ongoing care for cancer survivors, including managing late effects, mental health, and preventive health recommendations, helping analysts produce accurate results that support strategic planning, resource allocation, and performance benchmarking across organizations
Occupational health services use cancer treatment summaries to guide return-to-work planning, workplace adjustments, and phased return for cancer survivors completing treatment, allowing professionals to quantify outcomes systematically and compare scenarios using reliable mathematical frameworks and established formulas
Fertility clinics receive referrals from oncology teams pre-treatment for embryo, egg, or sperm cryopreservation in AYA patients facing gonadotoxic chemotherapy, supporting data-driven evaluation processes where numerical precision is essential for compliance, reporting, and optimization objectives
Cardio-oncology services use echocardiogram surveillance protocols for anthracycline and trastuzumab-treated survivors, identifying early cardiac dysfunction that can be treated before it progresses to symptomatic heart failure, which requires precise quantitative analysis to support evidence-based decisions, strategic resource allocation, and performance optimization across diverse organizational contexts and professional disciplines
Young adult cancer survivors (AYA)
Adolescent and young adult (AYA) cancer survivors aged 15–39 face unique challenges: fertility preservation is a priority before gonadotoxic treatment; educational and career disruption is common; psychosocial needs differ from older survivors; late effects have more years to develop. AYA-specific survivorship care programmes addressing fertility, peer support, employment, and mental health are recommended for this population.
Geriatric cancer survivorship
Older cancer survivors (>70 years) have overlapping cancer late effects, age-related comorbidities, polypharmacy, and frailty that compound survivorship challenges. Comprehensive geriatric assessment (CGA) is recommended at baseline and follow-up. Falls risk, cognitive decline, and functional dependence may accelerate post-treatment. Geriatric oncology liaisons and multidisciplinary team input are valuable in this population.
Fear of cancer recurrence (FCR)
FCR is the most prevalent and distressing psychological concern in cancer survivorship, affecting 60–70% of survivors at any time point. Clinically significant FCR (FCRI ≥13 on the short-form) requires psychological intervention. Evidence-based treatments include: Conquer Fear (a manualised 5-session CBT programme specifically for FCR); mindfulness-based cancer recovery; acceptance and commitment therapy. FCR does not resolve spontaneously with time in most individuals — active treatment is required.
Hereditary cancer syndromes in survivorship
Survivors diagnosed with hereditary cancer syndromes (BRCA1/2, Lynch syndrome, Li-Fraumeni, Cowden, VHL) require syndrome-specific enhanced surveillance for secondary malignancies, genetic counselling for family members, and discussion of risk-reducing interventions (prophylactic surgery, chemoprevention). Genetic testing should be offered to any newly diagnosed cancer patient who meets criteria — the survivorship phase is an opportunity to ensure genetic results have been actioned.
| Treatment Modality | Common Late Effects | Monitoring Tool/Test | Timeframe |
|---|---|---|---|
| Surgery (breast) | Lymphoedema, phantom pain, scar adhesions | Limb volume measurement, functional assessment | Ongoing |
| Anthracyclines (doxorubicin) | Cardiomyopathy (dose-dependent) | Echocardiogram; troponin | 1, 5, 10 years post-treatment |
| Trastuzumab | Reversible LV dysfunction | Echocardiogram every 3 months during treatment, annually after | During and post-treatment |
| Taxanes (paclitaxel, docetaxel) | Peripheral neuropathy | NRS, clinical examination, monofilament testing | Every 6 months for 2 years |
| Platinums (cisplatin) | Ototoxicity, renal impairment, neuropathy | Audiogram, GFR, neuropathy assessment | Annual for 5 years |
| Pelvic radiation | Bowel, bladder, sexual dysfunction, infertility | Bowel diary, ICIQ, FSFI/IIEF, FSH/LH | At 6 months, then annually |
| Neck radiation | Hypothyroidism, carotid disease, dysphagia | TSH annual; carotid Doppler at 5 years; FEES | Annual TSH; 5yr vascular |
| Hormonal therapy (AI) | Bone density loss, hot flushes, joint pain | DEXA scan at baseline and 2 years; DAS28 joints | Baseline and every 2 years |
What is a survivorship care plan?
A survivorship care plan (SCP) is a written document provided to cancer survivors at the completion of active treatment, summarising: the cancer diagnosis and treatments received; planned surveillance schedule; potential late effects and how to monitor for them; preventive health recommendations; and referrals to rehabilitation, psychological, and community support services. ASCO and NCCN recommend that all patients receive an SCP; NICE requires them in UK cancer services.
How common is 'chemo brain' (cancer-related cognitive impairment)?
Cognitive impairment following cancer treatment affects 20–30% of survivors and can persist for years. It is most commonly associated with chemotherapy (particularly regimens including methotrexate, high-dose alkylating agents, and combinations), but also radiation, hormonal therapies, and immunotherapy. Symptoms include difficulty concentrating, word-finding problems, reduced multitasking ability, and slowed processing speed. Neuropsychological testing, cognitive rehabilitation, and exercise have evidence of modest benefit.
What surveillance is recommended after breast cancer treatment?
ASCO and NCCN recommend: annual mammogram (and MRI if indicated); annual clinical breast exam for 5 years, then every 1–2 years; history and physical examination every 3–6 months for 3 years, then annually; DEXA bone density if on aromatase inhibitor therapy; cardiovascular surveillance for anthracycline-treated patients; thyroid function monitoring if neck radiation received. Routine tumour marker testing (CA 15-3, CEA) is not recommended for asymptomatic surveillance.
Does exercise reduce cancer recurrence risk?
Yes, with the strongest evidence in breast and colorectal cancer. Observational and RCT data show that regular aerobic exercise (150 min/week moderate intensity) is associated with 15–30% reduction in cancer-specific mortality and overall mortality in breast cancer survivors, and similar data exist for colorectal cancer. Mechanisms include reduction of insulin resistance, sex hormone levels, inflammation, and tumour growth factors. Exercise is now considered a standard component of survivorship care.
What is cardiotoxicity from cancer treatment and how is it monitored?
Cardiotoxicity encompasses a spectrum of cardiovascular effects from cancer treatment: anthracycline-induced cardiomyopathy (dose-dependent, risk increases steeply above cumulative doxorubicin >400 mg/m²); trastuzumab-induced reversible left ventricular dysfunction; radiation-induced coronary artery disease, pericarditis, and valvular disease; tyrosine kinase inhibitor-induced hypertension and QTc prolongation. Monitoring: echocardiogram at baseline, during, and after high-risk treatments; cardiovascular risk factor management; referral to cardio-oncology.
What are secondary malignancies and who is at risk?
Secondary malignancies are new primary cancers arising in cancer survivors — distinct from recurrence or metastasis. Risk factors include: prior radiation therapy (increased risk of solid tumours within the radiation field after 10–20 years); alkylating agent chemotherapy (acute myeloid leukaemia, myelodysplasia within 5–7 years); BRCA mutation carriers (bilateral breast cancer, ovarian cancer); smoking continuation after head/neck or lung cancer treatment. Secondary malignancy surveillance depends on the specific prior treatments and genetic risk factors.
How should sexual dysfunction in cancer survivors be addressed?
Sexual dysfunction affects 40–60% of cancer survivors and is among the most undertreated survivorship concerns. Assessment should be routine using validated tools (FSFI for women, IIEF for men, EPIC for prostate cancer). Treatment approaches: vaginal dryness/atrophy — topical oestrogen (generally safe in non-hormone-sensitive cancers), vaginal moisturisers, pelvic floor physiotherapy; erectile dysfunction — PDE5 inhibitors (sildenafil, tadalafil), vacuum erection devices, penile prosthesis; psychosexual therapy for psychological components.
What is financial toxicity in cancer survivorship?
Financial toxicity (cancer-related financial distress) refers to the economic burden of cancer treatment and its impact on quality of life and treatment adherence. Studies show that 30–40% of cancer survivors experience significant financial hardship, including depleted savings, debt, missed treatments due to cost, and reduced quality of life. Routine financial distress screening using validated tools (COmprehensive Score for financial Toxicity, COST) and referral to social work, financial counselling, and benefits advice is recommended.
Mẹo Chuyên Nghiệp
The transition from active treatment to survivorship is often described by patients as 'falling off a cliff' — loss of regular clinical contact and structured support at a time when fear of recurrence, late effects, and adjustment challenges peak. Proactively scheduling a survivorship consultation within 4–8 weeks of treatment completion (rather than waiting for the patient to request help) significantly improves engagement with survivorship care.
Bạn có biết?
The word 'survivor' as applied to cancer patients was popularised by Fitzhugh Mullan, an oncologist who was diagnosed with cancer himself and wrote a landmark 1985 article in the New England Journal of Medicine describing the 'seasons of survival' — acute, extended, and permanent. This personal and clinical perspective catalysed the founding of the National Coalition for Cancer Survivorship and transformed how the medical community thinks about life after cancer.